Nucleic Acid Therapeutics
ISSN:2159-3337

Nucleic Acid Therapeutics

NUCLEIC ACID THER
学科领域:医学
是否预警:不在预警名单内
是否OA:
录用周期:>12周,或约稿
新锐分区:医学3区
年发文量:31
影响因子:4.7
JCR分区:Q1

基本信息

《核酸治疗学》是该领域的领先期刊,专注于前沿基础研究、治疗应用和使用核酸或相关化合物改变基因表达的药物开发。该杂志研究了许多使用核酸作为治疗剂或修饰核酸用于治疗目的的新方法,包括:寡核苷酸、基因修饰、适体、RNA纳米颗粒和核酶。
2159-3337SCIE/Scopus收录
4.7
4.3
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学
3区
CHEMISTRY, MEDICINAL 药物化学
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验
3区
N/A
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科:BIOCHEMISTRY & MOLECULAR BIOLOGY
SCIE
Q1
78/320
学科:CHEMISTRY, MEDICINAL
SCIE
Q2
19/72
学科:MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
Q2
49/195
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科:BIOCHEMISTRY & MOLECULAR BIOLOGY
SCIE
Q1
78/321
学科:CHEMISTRY, MEDICINAL
SCIE
Q2
24/72
学科:MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
Q2
52/195
61
31
2%容易>12周,或约稿-BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
6.4%
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
96.77%28.42%-
CiteScore:8.20
SJR:1.499
SNIP:0.982
学科类别分区排名百分位
大类:Biochemistry, Genetics and Molecular Biology
小类:Genetics
Q1
65 / 348
大类:Biochemistry, Genetics and Molecular Biology
小类:Biochemistry
Q1
85 / 441
大类:Biochemistry, Genetics and Molecular Biology
小类:Drug Discovery
Q1
35 / 156
大类:Biochemistry, Genetics and Molecular Biology
小类:Molecular Medicine
Q1
44 / 177
大类:Biochemistry, Genetics and Molecular Biology
小类:Molecular Biology
Q2
112 / 410

期刊高被引文献

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2018.0747
Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2018.0772
Evaluation and Reduction of CRISPR Off-Target Cleavage Events
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2019.0790
A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2018.0756
In Vivo Silencing of MicroRNA-132 Reduces Blood Glucose and Improves Insulin Secretion.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2018.0763
Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2019.0794
Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2018.0773
Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2019.0810
Quantification of siRNA-Antibody Conjugates in Biological Matrices by Triplex-Forming Oligonucleotide ELISA.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2018.0770
Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2019.0779
Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2019.0796
Effect of Sugar 2′,4′-Modifications on Gene Silencing Activity of siRNA Duplexes
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2019.0792
Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in mdx Mice
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2019.0824
Formulation of Biocompatible Targeted ECO/siRNA Nanoparticles with Long-Term Stability for Clinical Translation of RNAi.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2019.0784
Double-Stranded DNA Fragments Bearing Unrepairable Lesions and Their Internalization into Mouse Krebs-2 Carcinoma Cells.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2019.0786
RNA Reduction and Hepatotoxic Potential Caused by Non-Gapmer Antisense Oligonucleotides.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2018.0741
Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2019.0806
Activation of Innate Immune Responses by a CpG Oligonucleotide Sequence Composed Entirely of Threose Nucleic Acid.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2018.0751
Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2019.0782
Metabolic Benefits of MicroRNA-22 Inhibition.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2019.0820
Antisense-Mediated Skipping of Dysferlin Exons in Control and Dysferlinopathy Patient-Derived Cells.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2019.0788
Expression of TNRC6 (GW182) Proteins Is Not Necessary for Gene Silencing by Fully Complementary RNA Duplexes
来源期刊:Nucleic Acid TherapeuticsDOI:10.1089/nat.2019.0815
Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2018.0740
Development of a Nanostructured RNA/DNA Assembly as an Adjuvant Targeting Toll-Like Receptor 7/8.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2019.0787
Endocytosis Controls Small Interfering RNA Efficiency: Implications for Small Interfering RNA Delivery Vehicle Design and Cell-Specific Targeting.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2019.0804
G-Quadruplex Structure Improves the Immunostimulatory Effects of Cytosine-Phosphate-Guanine Oligonucleotides.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2018.0761
Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials.
来源期刊:Nucleic acid therapeuticsDOI:10.1089/nat.2019.0781

相关文章

2026年3月发布(新锐分区)
大类学科小类学科Top期刊综述期刊
医学3区
BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学
3区
CHEMISTRY, MEDICINAL 药物化学
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验
3区
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学2区
BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学
2区
CHEMISTRY, MEDICINAL 药物化学
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验
3区
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学2区
BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学
2区
CHEMISTRY, MEDICINAL 药物化学
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验
3区